The inefficiencies of the current pipeline from discovery to clinical approval of drugs demand a surrogate method to indicate adverse drug reactions, e.g. liver damage. Organ-on-chip (OOC) models would be an ideal, rapid, and human-specific alternate, which would render animal testing obsolete. The ground-breaking ability of OOCs and Multi-OOC constructs is the accurate simulation of the in vivo conditions of human organs leading to precise drug screens for cytotoxicity and/or drug efficacy at a faster pace and lesser cost. Here we discuss the innovation, architecture, and the progress of OOCs towards human body-on-a-chip.

Nanomaterials have been proposed as key components in biosensing, imaging, and drug delivery since they offer distinctive advantages over conventional approaches. The unique chemical and physical properties of graphene make it possible to functionalize and develop protein transducers, therapeutic delivery vehicles, and microbial diagnostics. In this study, we evaluate reduced graphene oxide as a potential nanomaterial for quantification of microRNAs including their structural differentiation in vitro in solution and inside intact cells. Our results provide evidence for the potential use of graphene nanomaterials as a platform for developing devices that can be used for microRNA quantitation as biomarkers for clinical applications.

Low-density, highly porous graphene/graphene oxide (GO) based-foams have shown high performance in energy absorption applications, even under high compressive deformations. In general, foams are very effective as energy dissipative materials and have been widely used in many areas such as automotive, aerospace and biomedical industries. In the case of graphene-based foams, the good mechanical properties are mainly attributed to the intrinsic graphene and/or GO electronic and mechanical properties. Despite the attractive physical properties of graphene/GO based-foams, their structural and thermal stabilities are still a problem for some applications. For instance, they are easily degraded when placed in flowing solutions, either by the collapsing of their layers or just by structural disintegration into small pieces. Recently, a new and scalable synthetic approach to produce low-density 3D macroscopic GO structure interconnected with polydimethylsiloxane (PDMS) polymeric chains (pGO) was proposed. A controlled amount of PDMS is infused into the freeze-dried foam resulting into a very rigid structure with improved mechanical properties, such as tensile plasticity and toughness. The PDMS wets the graphene oxide sheets and acts like a glue bonding PDMS and GO sheets. In order to obtain further insights on mechanisms behind the enhanced mechanical pGO response we carried out fully atomistic molecular dynamics (MD) simulations. Based on MD results, we build up a structural model that can explain the experimentally observed mechanical behavior.

The mechanism of electrical noise in transition metal dichalcogenides (TMDCs) has mostly been attributed to charge carrier fluctuations between the oxide traps and the conducting channel, in accordance with the McWhorter model. However, the original McWhorter model was formulated for diffusive transport with conducting carriers having extended electronic wave functions. Our work serves to generalize the McWhorter mechanism to include strongly localized systems such as the TMDC family and provides an explanation for the unusual exponential behavior of noise magnitude with temperature.

This article features the importance of nanomaterial–protein interfaces, with a special interest on two-dimensional (2D) nanomaterials, for next generation sensors and electronics. Graphene, the first isolated and studied 2D nanomaterial, is taken as the material of most interest and then focused on its engineering by heteroatom doping. The success of graphene engineering for sensors widened the search for better and efficient biosensor platforms of other layered materials such as boron nitride and transition metal dichalcogenides. But functionalization of 2D backbones with biomolecules often ends up with the disruption of the biological activities due to various reasons. This has to be fundamentally studied and corrected for the clinical implementation of these materials based novel sensing platforms in point-of-care devices and micro-fluidic chips. At the end, importance of various 2D materials–biomolecule interfaces is discussed, and MoS2 based label-free biosensor is highlighted. A method for the modification of MoS2–biomolecule interaction via covalent functionalization of oxygen functionalities in MoS2 is also proposed.

The emergence of 2-dimensional (2D) materials could herald numerous advanced scientific methodologies for both fundamental and applied research. These ultrathin materials can be functionalized and, thus, have the potential to make new devices and sensors that are both highly efficient and sensitive. In addition to being mechanically robust, the 2D materials can be engineered to provide sensor architectures that further increase their inherent high surface area by creating 3D geometries using layer by layer assembly to make stacked devices that could potentially be transparent. The increased sensor surface area would deliver increased signal-to-noise and sensitivity. Here highly sensitive and selective electrochemical detection of bio-analytes using some of engineered 2D materials such as graphene nano-ribbons, fluorinated graphene, and molybdenum disulfide is presented. It is found that surface moieties, defects and surface charges in these ultra-thin layers result in enhanced electron transfer kinetics between the electrodes and biomolecules. This in turn results in an oxidation or reduction of biomolecules with a high peak current, indicating the possible uses of 2D materials for various point-of-care devices. A novel stable 3D electrode geometry has been found to have enhanced heterogeneous electron transfer properties compared to 2D electrodes and provides evidence that electrode geometry and surface area could significantly impact the performance of biosensors.

The need for improved medical sensors based on lab-on-a-chip technologies has increased significantly because of the dramatic growth in the number of people with chronic diseases and the associated costs for their healthcare. Development and initial results of a hybrid plastic microfluidic device with an integrated graphene-protein biosensor chip for use in point-of-care (POC) is described. The initial prototype is a glucometer that uses optimized glucose oxidase bound to a graphene field effect sensor. Technologies required for development of the prototype include modification of the glucose oxidase for improved performance by protein engineering, methods to bind the enzyme to the graphene attached to the silicon oxide surface of sensor chip, and integration into a thermoplastic microfluidic device. Initial results indicate the prototype glucometer can measure glucose concentrations from low physiological levels to molar concentrations.